WorldCat Identities

Jacobzone, Stephane

Overview
Works: 53 works in 159 publications in 2 languages and 1,445 library holdings
Genres: Conference papers and proceedings  Medical statistics  Cross-cultural studies 
Roles: Other, Author, Director, Thesis advisor, Redactor
Classifications: HD74, 362.6309177
Publication Timeline
.
Most widely held works by Stephane Jacobzone
Care allowances for the frail elderly and their impact on women care-givers by Jane Jenson( Book )

20 editions published in 2000 in English and held by 178 WorldCat member libraries worldwide

This report discusses the impact of care allowances on women care-givers. These programmes, involving some payment for care in informal care settings, have recently been introduced in several OECD Member countries. While their primary goal has been to help older persons in need of care, their consequences for the persons providing care also deserve to be analysed. The bulk of informal care is provided by women care-givers. In this respect, long-term care systems involve a partnership between formal care systems, the state, and the family, in order to provide a continuum of care. This also renders the analysis very complex. The main objective of the paper is to answer the question: what is the impact for women care-givers of various models of care allowances for the frail elderly? These care allowances have been primarily instituted to address the needs of older persons for care, as well as to offer some compensation for caring responsibilities. Apart from these initial goals
Pharmaceutical policies in OECD countries : reconciling social and industrial goals by Stephane Jacobzone( Book )

17 editions published in 2000 in English and held by 178 WorldCat member libraries worldwide

Regulation of the pharmaceutical sector needs to reconcile private and social objectives. Public intervention pursues multiple goals which relate to both health and industry policy. Many OECD Governments are also heavily involved as buyers of pharmaceuticals in publicly-financed health care systems. This paper describes recent trends in pharmaceutical expenditure and financing in a first chapter. A second chapter discusses the economics of pharmaceutical markets. A third chapter provides a review of national policies and their attempts to balance public and private objectives. Pharmaceutical expenditure has been rising steadily as a share of GDP since 1970. However, total health expenditure has also risen. As a result, pharmaceutical expenditure has, on average, maintained its share of total health expenditure in the OECD, close to 15 %. Across countries, pharmaceutical expenditure per capita depends on relative incomes but is also influenced by institutional features. The pharmaceutical
Australia 2010 : towards a seamless national economy( )

1 edition published in 2010 in English and held by 136 WorldCat member libraries worldwide

This review of regulatory reform in Australia comes at the right time to capture the attention of the OECD community. Australia has successfully weathered the worst effects of the current economic crisis. The resilience of the Australian economy, in the face of the deepest and most widespread recession in over fifty years in OECD countries, can in part be attributed to Australia's current and past regulatory reforms. Australia has built strong governance foundations for the development of good regulatory management and competition policies, which are likely to be conducive to economic growth. It aims to reinvigorate a wide agenda of national reforms and to embed past reform achievements in new working arrangements between the Commonwealth and the States. This reform agenda is likely to yield substantial economic benefits for years to come, but demands joint participation and commitment from both the Commonwealth and all States. Maintaining the momentum for reform is a critical challenge, which requires a strategic vision as well as strenuous efforts to promote change and to establish a culture of continuous regulatory improvement. Australia is one of many OECD countries to request a broad review by the OECD of its regulatory practices and reforms. This review presents a general picture, set within a macroeconomic context, of regulatory achievements and challenges, including regulatory quality at the Commonwealth level as well as across levels of government, competition policy and market openness. It also provides a special focus on Commonwealth-state relationships
Italy : better regulation to strengthen market dynamics( )

2 editions published in 2009 in English and held by 134 WorldCat member libraries worldwide

This review presents a general picture of the overall regulatory reform frameworks in Italy, examining quality regulation, competition policy and professional services. It also offers a special focus on multi-level governance, where key issues include local public services, commercial distribution, local transport and energy. The review finds that Italy made significant progress using regulatory reform since 2001. Administrative simplification and the increasing role of competition policy, combined with devolution of state powers to regions, helped. But the key challenges for regulatory policy and its implementation include: enforcement, capacity in the civil service, impact analysis for evidence-based decision-making, and building a culture of consultation. The global economic crisis could present an opportunity for Italy to further clarify how the state intervenes in the economy, to improve multi-level co-ordination, and to expand competition in specific sectors.--Publisher's description
Survey of pharmacoeconomic assessment activity in eleven countries by Michael Dickson( )

8 editions published in 2003 in English and held by 97 WorldCat member libraries worldwide

Policy-makers responsible for publicly-funded drug programmes face continual pressures between the demand to accommodate a steady stream of new and more effective drugs and the ongoing requirement to control costs. In the face of these pressures, a growing number of OECD countries are applying 'pharmacoeconomic assessment' (health technology assessment for drugs) - to new drugs to guide decisions about accepting such products for reimbursement under their public programme, or to inform negotiations about pricing. This paper provides an analytical overview of the developing practice of pharmacoeconomic assessment in eleven OECD countries. It looks at the objectives of the activity, some of its processes and some of its impacts. It does this by drawing on a literature review and on an exploratory survey of the activities of pharmacoeconomic agencies in the eleven countries. It also reviews briefly the state of pharmacoeconomic assessment in the United States. The main conclusions are as
Pharmaceutical use and expenditure for cardiovascular disease and stroke : a study of 12 OECD countries by Michael Dickson( )

10 editions published in 2003 in English and held by 86 WorldCat member libraries worldwide

This study presents the results of a joint analysis of patterns of consumption, expenditure, and unit expenditure for a core set of drugs aimed at preventing and treating cardiovascular disease. The current study examines the relationships among three pharmaceutical variables (expenditure, volume of drug use, and unit expenditure) classified according to eight therapeutic categories which are specific for the prevention and treatment of cardiovascular disease and stroke. It covers an 11-year time period, and specifies relevant country-specific structural features in a sample of 12 OECD countries. The data presented in this report show how the three descriptive pharmaceutical variables vary across these countries. The study also contains a preliminary exploration of factors associated with variation in these variables across countries and through time. Findings for each of the eight cardiovascular disease and stroke drug therapeutic categories investigated in this study are
The changing health system in France by Yukata Imai( Book )

5 editions published in 2000 in English and held by 83 WorldCat member libraries worldwide

OECD study of cross-national differences in the treatment, costs and outcomes of ischaemic heart disease by Pierre Moise( )

5 editions published in 2003 in English and held by 58 WorldCat member libraries worldwide

The Ageing-Related Diseases study compares treatment trends and health outcomes on a disease-by-disease basis. Most of the day-to-day decisions that determine health care system performance are made in treating specific diseases. Therefore, the ARD's bottom-up approach to comparing health care system performance at the disease level, rather than the more common top-down approach, goes to the heart of health care system performance. This paper presents such an analysis for ischaemic heart disease. There is considerable variation in treatment trends for the same diseases across countries and much of this variation can be explained by differences in structural characteristics of health care systems. A disease-level analysis begins with an examination of these characteristics: the economic incentives, policies and regulations that affect individual providers' decisions for treating a specific disease, defining a particular health care system's approach. In order to properly assess
Regulatory Management Systems Across OECD Countries : Indicators of Recent Achievements and Challenges( )

7 editions published in 2007 in English and held by 56 WorldCat member libraries worldwide

This Working Paper is structured in two sections. The first section presents the contributions and limits of composite indicators of regulatory management systems. The second section provides an overview of regulatory management systems, including regulatory policies, institutions, processes and tools. This report assesses regulatory policies in member countries as well as their regulatory management systems using the 1998 and 2005 indicators. The results complement the results presented in Working Paper N°4, "Indicators of Regulatory Management Systems" and also contributed to the OECD project on Government at a Glance (see www.oecd.org/gov/indicators/govataglance)
Indicators of Regulatory Management Systems by Stephane Jacobzone( )

6 editions published in 2007 in English and held by 54 WorldCat member libraries worldwide

This report presents detailed results on the quality of regulatory management systems, following the survey conducted in 2005-6. The goal of this report is to compare regulatory quality assurance systems; to measure progress and understand trends over time across countries, and to identify general patterns of regulatory management practice. Following initial discussions over the survey instrument in 2005, they survey was circulated in June 2005 and the results, corresponding to 2005, were then collected with final submissions received in Spring 2006. This paper has been revised following comments received from delegates in the Autumn 2006 and Spring 2007. The current set of results also links to previous regulatory governance indicators collected by the OECD in 1998 and 2000. Some of the early phase issues in terms of checks and a correction of the understanding of the concepts led to a revision of previous 1998 estimates. Therefore, this report is based on the corrected results for 1998 and 2000 received from the countries that had been surveyed then. These results also feed into the OECD Project on "Management in Government" (OECD (2007), "Towards Better Measurement of government", OECD Working Papers on Public Governance, 2007/2, OECD Publishing. Doi:110.1787/301575636734). This paper restricts itself to a descriptive presentation of the materials collected. Further methodological work will be undertaken as this project evolves to conduct more technical statistical analysis and build aggregated indicators. This work benefited from insights and comments from OECD colleagues. The authors are particularly grateful to Rolf Alter, Josef Konvitz, Glen Hepburn and Nick Manning for their comments, as well as to Peter Ladegaard who participated in some of the initial work. The authors are also indebted to Sander Wagner for statistical assistance
Strengthening the Institutional Setting for Regulatory Reform : the Experience from OECD Countries by César Córdova-Novion( )

6 editions published in 2011 in English and held by 54 WorldCat member libraries worldwide

This Working Paper analyses the institutional setting for regulatory reform. It is the first comprehensive analysis of regulatory oversight bodies. The analysis adopts a functional approach through four core functions: i) oversight of the rule-making process; ii) assisting rule makers in their evidence-based analysis; iii) challenging the quality of regulatory proposals; iv) advocating for quality/better regulation. The report analyses the key factors contributing to success, as well as elements for the credibility of regulatory oversight. The report also finds that regulatory quality oversight represents a tool for policy coherence for countries and needs to be articulated with other core policies, such as microeconomic and competition-oriented reforms, as well as overall reforms of the public administration. Forging of a political constituency requires active communications, political buy-in and support from a champion, and an external constituency of interested parties to support advocacy. The report concludes with a possible checklist for policy makers interested in consolidating regulatory oversight in their respective national settings
Assessing the Impact of Regulatory Management Systems : Preliminary Statistical and Econometric Estimates( )

4 editions published in 2010 in English and held by 53 WorldCat member libraries worldwide

This Working Paper presents preliminary analytical estimates using the 1998 and 2005 surveys of indicators of systems for the management of regulatory quality. Two broad dimensions are found in regulatory management systems using Factor Analysis, and Principal Component Analysis. The first reflects an integrated approach to ex ante assessment, with the use of tools such as formal consultation and regulatory impact analysis as well as institutions for regulatory oversight, training and capacity building. The second focuses on the stock of regulation, with administrative simplification, streamlining licences and permits, etc. These data are correlated with other available datasets on regulatory frameworks, including the OECD indicators of Product Market Regulations, subsets of the Doing business and Worldwide Governance Indicators (WGI) from the World Bank and the Global Competitiveness Index (GCI) from the World Economic Forum. Finally, the report presents some preliminary regressions with reduced forms, including fixed and random effects, linking the indicators to macroeconomic indicators. The findings tend to support the view that improvements in regulatory management system quality yield significant economic benefits
Tools for Regulatory Quality and Financial Sector Regulation : a Cross-Country Perspective by Julia Black( )

6 editions published in 2009 in English and held by 53 WorldCat member libraries worldwide

This report provides a comparative perspective on the application of quality regulation principles to financial sector regulators, in the US, Canada, Australia, the UK and France. The report compares key provisions of the codes of the Basle Committee and IOSCO, with the OECD's 2005 Guiding Principles for Regulatory Quality and Performance, and the 2009 Policy Framework for Effective and Efficient Financial Regulation (PFEEFR). The report analyses the independence and accountability of the regulators, as well as their powers. The analysis focuses on requirements for ex ante and ex post regulatory impact analyses, including burden reduction; for transparency and communication of decision making, as well as co-ordination and regulatory review; for improving the regulatory system over time and for regulating conflicts of interest. The report finds variation in the formal arrangements, and respective practices. It also finds that the requirements related to better regulation principles are often implemented too late in the decision-making process when regulations are set at the international level
Économie de la santé : trajectoires du futur by Institut national de la statistique et des études économiques (France)( Book )

5 editions published in 1997 in French and held by 48 WorldCat member libraries worldwide

Stroke care in OECD countries : a comparison of treatment, costs, and outcomes in 17 countries by Lynelle Moon( )

7 editions published in 2003 in English and held by 42 WorldCat member libraries worldwide

The Ageing-Related Diseases study compares health care systems by examining treatment trends and health outcomes on a disease-by-disease basis. Most of the day-to-day decisions that determine health care system performance are made in treating specific diseases. Therefore, the ARD's bottom-up approach to comparing health care system performance at the disease level, rather than the more common top-down approach, goes to the heart of health care system performance. This paper presents such an analysis for stroke. There is considerable variation in treatment trends for the same diseases across countries and much of this variation can be explained by differences in structural characteristics of health care systems. A diseaselevel analysis begins with an examination of these characteristics: the economic incentives, policies and regulations that affect individual providers' decisions for treating a specific disease, defining a particular health care system's approach. In order
The changing health system in France by Yutaka Imai( )

9 editions published in 2000 in English and held by 32 WorldCat member libraries worldwide

This paper reviews the performance of French health care system from an economic viewpoint. It also provides some policy recommendations. The health system in France is regarded as delivering high quality services, with freedom of choice and generally no waiting lists for treatments. Access to medical services is equal among the population and, unlike in some other countries, people can get the treatments they need irrespective of their social status or work situation. It is therefore not surprising that the French population is relatively satisfied with the health system. As this paper points out, however, this high quality comes at a price: health expenditure in relation to GDP is among the highest in the OECD and risks increasing further in the future in the absence of adequate measures. Past reform efforts, which have shifted the cost to the patient through higher out-of-pocket payments, have proved ineffective and raised equity questions. A new approach is therefore
The Changing Health System in France by Yutaka Imai( )

1 edition published in 2000 in English and held by 27 WorldCat member libraries worldwide

This paper reviews the performance of French health care system from an economic viewpoint. It also provides some policy recommendations. The health system in France is regarded as delivering high quality services, with freedom of choice and generally no waiting lists for treatments. Access to medical services is equal among the population and, unlike in some other countries, people can get the treatments they need irrespective of their social status or work situation. It is therefore not surprising that the French population is relatively satisfied with the health system. As this paper points out, however, this high quality comes at a price: health expenditure in relation to GDP is among the highest in the OECD and risks increasing further in the future in the absence of adequate measures. Past reform efforts, which have shifted the cost to the patient through higher out-of-pocket payments, have proved ineffective and raised equity questions. A new approach is therefore
Survey of Pharmacoeconomic Assessment Activity in Eleven Countries by Michael Dickson( )

1 edition published in 2003 in English and held by 12 WorldCat member libraries worldwide

Policy-makers responsible for publicly-funded drug programmes face continual pressures between the demand to accommodate a steady stream of new and more effective drugs and the ongoing requirement to control costs. In the face of these pressures, a growing number of OECD countries are applying 'pharmacoeconomic assessment' (health technology assessment for drugs) - to new drugs to guide decisions about accepting such products for reimbursement under their public programme, or to inform negotiations about pricing. This paper provides an analytical overview of the developing practice of pharmacoeconomic assessment in eleven OECD countries. It looks at the objectives of the activity, some of its processes and some of its impacts. It does this by drawing on a literature review and on an exploratory survey of the activities of pharmacoeconomic agencies in the eleven countries. It also reviews briefly the state of pharmacoeconomic assessment in the United States. The main conclusions are as
Ageing and Care for Frail Elderly Persons : an Overview of International Perspectives by Stephane Jacobzone( )

1 edition published in 1999 in English and held by 12 WorldCat member libraries worldwide

This paper examines the various constraints which OECD Member countries must now deal with, faced with the prospects of rapid growth in the number of frail elderly persons. It pays particular attention to recent trends in disability. Most of the available cross-country evidence shows trends towards better functional health in older populations, although the magnitude of the gains and their significance need further assessment. In this context, this paper advocates an "active ageing" approach to long-term care policies. It provides some rough estimates of the macroeconomic costs of long-term care. It also presents some indicators of public/private financing and institutionalisation rates. The public costs of providing long-term care are estimated to be relatively modest as a proportion of GDP (of the order of 1 or 2 per cent or less). However, much care for the frail elderly is provided through informal care-giving arrangements which are not reflected in official figures
Pharmaceutical Use and Expenditure for Cardiovascular Disease and Stroke : a Study of 12 OECD Countries by Michael Dickson( )

1 edition published in 2003 in English and held by 11 WorldCat member libraries worldwide

This study presents the results of a joint analysis of patterns of consumption, expenditure, and unit expenditure for a core set of drugs aimed at preventing and treating cardiovascular disease. The current study examines the relationships among three pharmaceutical variables (expenditure, volume of drug use, and unit expenditure) classified according to eight therapeutic categories which are specific for the prevention and treatment of cardiovascular disease and stroke. It covers an 11-year time period, and specifies relevant country-specific structural features in a sample of 12 OECD countries. The data presented in this report show how the three descriptive pharmaceutical variables vary across these countries. The study also contains a preliminary exploration of factors associated with variation in these variables across countries and through time. Findings for each of the eight cardiovascular disease and stroke drug therapeutic categories investigated in this study are
 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.76 (from 0.67 for Italy : be ... to 0.88 for The changi ...)

Italy : better regulation to strengthen market dynamics
Covers
Alternative Names
Jacobzone, S.

Jacobzone, S. (Stephane)

Jacobzone, Stéphane

Languages
English (117)

French (5)